Profiel
Andrew King worked as a Senior Director of Discovery & Translational Biology at Ardelyx, Inc. He then served as the Chief Scientific Officer at Chinook Therapeutics, Inc. from 2021 to 2023.
Dr. King holds a doctorate degree from Michigan State University and an undergraduate degree from Murdoch University.
Eerdere bekende functies van Andrew King
| Bedrijven | Functie | Einde |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 09-08-2023 |
| ARDELYX, INC. | Corporate Officer/Principal | - |
Opleiding van Andrew King
| Murdoch University | Undergraduate Degree |
| Michigan State University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ARDELYX, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
